Infinity Pharmaceuticals

Infinity Pharmaceuticals Eurther information available at http //www.infi. com/ (accessed on 14.12.2010). 

Retaspimycin (IPI-504) 70 (Infinity Pharmaceuticals) is being evaluated in a Phase III trial to treat patients with gastrointestinal stromal tumours that have failed previous treatments with imatinib and/or sunitinib.164 Retaspimycin 70 is a hydroquinone derivative of tanespimycin 68 that has significantly improved solubility while retaining potent Hsp90 binding activity.165 167... 

Infinity Pharmaceuticals also reported the highly soluble geldanamycin-derived 17-amino-17-desmetho5tygeldanamycin 5 (17-AG also known as... 

Infinity Industries McNeil Consumer Healthcare Par Pharmaceuticals Penick... 

In recent years pharmaceutical scientists have participated in lively discussions about how present methods of bioequivalency determination might legitimately and advantageously be modified. For example, the question of whether it is necessary to always take plasma samples so that AUC at the end of the test is at least 90% of AUC at time infinity has been explored [7,8], Statistical aspects of this and other possible methods of modifying protocol design are covered in a most useful book published in 1999 and in several papers [8-10,22],... 

Bioequivalence means that two or more chemically or pharmaceutically equivalent products produce comparable bioavailability characteristics in any individual when administered in equivalent dosage regimen (parameters compared include the area under the plasma concentration versus time curve (AUC) from time zero to infinity (AUC)q, maximum plasma concentration and the time of peak concentration). 

Dhanarajn MD, Jayaknmar R, Vamsadhara C. Infinence of manufacturing parameters on development of contraceptive steroid loaded injectable microspheres. Chemical and Pharmaceutical Bulletin. Angnst 2004 52(8) 976-979. PnbMed PMID 15304994. 

One can regard the concept of individual risk scores similar to letting the number of subgroup go to infinity so that each individual forms their own subgroup. To develop a risk calculator for a clinically important event after exposure to a pharmaceutical product will require a large amount of data. In our opinion, the latter may become possible with advancements in computing technology and our ability to access data in claims database and electronic medical records. Statisticians should participate in such efforts to ensure that appropriate statistical methods are used to address possible sources of bias, especially selection bias, that are often associated with data from nonrandomized sources. 

---